• AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development

  • May 1 2025
  • Length: 44 mins
  • Podcast

AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development

Listen for free

View show details

  • Summary

  • In this second part of our AI-focused series in collaboration with Arnold & Porter, Shelly and Wayne chat with Howard Sklamberg, Partner at Arnold & Porter; Eva Temkin, Partner at Arnold & Porter; and Marko Topalovic, Chief AI Officer at Clario, which recently acquired ArtiQ, where he was Founder and CEO. Together, they discuss how AI can accelerate drug discovery and design; how AI could be used in the clinical trial process; how FDA could use AI to evaluate medical product manufacturers’ data integrity operations and in inspections; how AI could play a part in product applications; and much more.

    Access Arnold & Porter’s recent AI survey here.

    This episode and the rest of our series do not include the usual Headlines and Resources Links segments.

    To subscribe or find out more information about our podcast, visit FDAWatch.net.

    Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at info@fdawatch.net.

    Music by Dvir Silver from Pixabay.
    Show More Show Less
Show More Show Less
activate_mytile_page_redirect_t1

What listeners say about AI, Medical Products & FDA, Part 2: AI Discovery, Design & Development

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.